Diagnostic Significance of FDG PET/CT Dynamic Imaging in Detecting Metastatic Lymph Nodes With Papillary Thyroid Cancer.

  • STATUS
    Recruiting
  • days left to enroll
    32
  • participants needed
    50
  • sponsor
    Fifth Affiliated Hospital, Sun Yat-Sen University
Updated on 4 October 2022
platelet count
cancer
carcinoma
pet/ct scan
fdg pet
thyroid carcinoma
papillary thyroid carcinoma
papillary carcinoma

Summary

The aim of this study is to make up for the gap by performing a dynamic scan of <Sup>18<Sup>F-FDG PET/CT on newly diagnosed patients with papillary thyroid carcinoma. Pathological and genomic studies are performed. The differences between metastatic central lymph nodes images and tissues are compared at the same time. <Sup>18<Sup>F-FDG PET/CT dynamic imaging is explored in metastatic central lymph nodes with papillary thyroid cancer for the diagnostic value.

Description

Thyroid cancer is the most common malignant tumor in human endocrine system, accounting for 0.2% ~ 1.0% of malignant tumors .According to the global cancer report released by the world health organization (WHO) in 2014, 50% of the new cases of thyroid cancer are papillary thyroid cancer (PTC). In recent years, the incidence of thyroid cancer in China shows an increasing trend, especially the composition ratio of thyroid micro-papillary carcinoma with the focal diameter <1 cm increases rapidly.Although PTC has a good prognosis, according to a Meta analysis , PTC lymph node metastasis rate is as high as 28.0%.The central lymph node is the most common metastatic site of papillary thyroid carcinoma.In addition, it has been reported in literature that lymph nodes in the central region are the first stop of thyroid papillary carcinoma metastasis (i.e., sentinel lymph nodes), and lymph nodes metastatic to this point are prone to infringe the peripheral esophagus, trachea and recurrent laryngeal nerve at an early stage.A large number of clinical cases have confirmed that lymph node metastasis of thyroid cancer significantly increases the local recurrence rate after surgery.More studies have shown that regional lymph node metastasis increases mortality.Therefore, the treatment of lymph node metastasis should not be ignored in PTC patients.However, at present, preoperative imaging has certain limitations in the judgment of lymph node metastasis in the central region : ultrasound has advantages in the judgment of lymph node metastasis in the peripheral group, but poor display in the central group.Although MRI scan of head and neck can be multi-directional and multi-sequence imaging, and the resolution of soft tissue is high, it is not good at showing calcification.Conventional CT alone based on lymph node morphology to determine metastasis also has some limitations;Positron emission tomography (PET) sensitivity was < 40%.Although one study showed that the probability of non-missed diagnosis of lymph nodes in central PTC region by thin slice CT scan was 100%, the specificity was low and the study was retrospective.Therefore, b-ultrasound, MRI, CT, PET and other auxiliary examinations have not been able to effectively detect all central metastatic lymph nodes before surgery.For management of cervical lymph nodes ,2015 American Thyroid AssociationATA guidelines show that thyroid+therapeutic area lymph node dissection should be undertaken if in central or lateral lymph nodes are involved.Chinese guidelines recommend that, in order to avoid operative complications as far as possible (i.e. effective retainment of the parathyroid gland and recurrent laryngeal nerve), regardless of the size of the primary thyroid lesion, lymph node dissection in the central area on the same side of the lesion should be performed at least.However, in 2017, the second edition of National Comprehensive Cancer Network(NCCN) thyroid tumor guidelines believed that if lymph nodes in the central region were negative, preventive central region lymph node dissection was not recommended.Above allthere is so much controversy over lymph node dissection in the central region. Thereforeit is of great significance to effectively evaluate the preoperative lymph nodes station in the central region of thyroid papillary carcinoma.

Early dynamic imaging examination of <Sup>18<Sup>F-FDG PET/CT can be defined as a imaging method to detect the status of radioactive tracer (<Sup>18<Sup>F-FDG) which travels with the blood flow and is continuously absorbed and excreted by organs (or diseased) tissues after being introduced into the body in the early stage.This development reflects the change of <Sup>18<Sup>F-FDG activity with time in the early stage of entering the body, and can provide information about the dynamic change of tracer metabolism and distribution in tissues with time, so that it can provide more metabolic and distribution details of tumor lesions and metastatic lesions than static scanning.At present, many studies have shown that <Sup>18<Sup>F-FDG PET/CT early dynamic imaging technology can effectively improve the sensitivity of hepatocellular carcinoma ,renal cell carcinoma and other tumors.More amazingthere may be more advantages in evaluating lymph node metastasis.The blood supply of lymph nodes metastatic of thyroid papillary carcinoma is abundant, which helps to locate the metastatic tumor lymph node.Howeverthere is no relevant study.Now , investigators plan to observe the significance of the method to evaluate the central lymph node metastasis in thyroid papillary carcinoma as well as the intrinsic correlations between the significance and postoperative pathological results ,which may help to develop surgical strategy by preoperative evaluation and avoiding additional dissection.

Details
Condition POSITRON EMISSION TOMOGRAPHY, Thyroid Adenoma, Thyroid Cancer, emission computed tomography, head and neck cancer, head and neck cancer, Thyroid disorder, Thyroid Disease, Thyroid Disorders, Lymph Node Metastasis, Lymph Node Metastases, Thyroid Disease, Thyroid Disorders, Thyroid Cancer, thyroid carcinoma, pet scan, pet imaging, pet scans
Treatment <Sup>18<Sup>F-FDG PET/CT dynamic scan, B-ultrasonography
Clinical Study IdentifierNCT03830242
SponsorFifth Affiliated Hospital, Sun Yat-Sen University
Last Modified on4 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Accurately diagnosing primary papillary thyroid cancer according to pathological diagnostic criteria
Thyroid papillary carcinoma was suspected by thyroid ultrasound text and/or neck CT
The age is more than 18 years old and less than 65 years old. There is no gender restriction
Untreated patients who have not received surgery, interventional therapy,chemotherapy, biotherapy, and radiation therapy
Physical condition score of Eastern Cooperative Oncology GroupECOG: 0-2; no major organ dysfunction; oxygen partial pressure 10.64 kilopascalkPa; white blood cell count 4 109/L; hemoglobin 9.5g/dL; neutrophil absolute count 1.5 109 / L; platelet count 100 109 / L; total bilirubin 1.5 times of the upper limit of normal value;creatinine 1.25 times of the upper limit of normal value; and creatinine clearance 60ml / min
Be able to obtain complete follow-up information, understand the situation of this study and sign informed consent

Exclusion Criteria

Poorly controlled diabetics (fasting blood glucose levels > 200 mg/dL). In addition to four types of malignant tumors that can be treated with radical resection, such as cervical cancer in situ, basal or squamous cell skin cancer, (breast) ductal carcinoma in situ, and organ localized prostate cancer, suffering from any other malignant tumors within 5 years. Breastfeeding and/or pregnant women
Patients with severe bleeding tendencies (prothrombin time less than 50%,cannot be corrected by treatment with vitamin K, etc.)
Recent severe hemoptysis, severe cough, dyspnea or patients are not able to cooperate
People with severe emphysema, pulmonary congestion, and pulmonary heart disease
Researchers believe that the subject may not be able to complete this study or may not be able to comply with the requirements of this study (for management reasons or other reasons)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note